Biosimilar breast cancer drug tested in everyday clinics
NCT ID NCT03892655
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 170 women with early-stage HER2+ breast cancer who are receiving the biosimilar drug Zedora after surgery. Researchers want to see how well it prevents the cancer from coming back and how safe it is in real-world settings, where patients may have other health issues or trouble sticking to treatment. The goal is to confirm that Zedora works as well in practice as it did in earlier trials for advanced cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
biosimilar trastuzumab (Zedora)
What this could lead to
If successful, this study could confirm that Zedora is a safe and effective option for treating early-stage HER2+ breast cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small (170 patients) and only includes Brazilian women, which may limit how well the findings apply to other groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Andrea Juliana Pereira de Santana Gomes
Natal, Rio Grande do Norte, 59075740, Brazil
-
Charles Alain Cordova Pinto
Lages, Santa Catarina, Brazil
-
Cláudio Rocha
Teresina, Piauí, 64049-200, Brazil
-
Cristina de Deus Anjos Tavares Sampaio
Campo Grande, Mato Grosso, Brazil
-
Daniel Fontes Santos de Teive e Argolo
Salvador, Estado de Bahia, 41810570, Brazil
-
Daniel Grabarz
Mogi das Cruzes, São Paulo, 08730500, Brazil
-
Kaique Almeida
São Paulo, São Paulo, Brazil
-
Karina Costa Maia Vianna
Curitiba, Paraná, Brazil
-
Luis Eduardo Rosa Zucca
Três Lagoas, Mato Grosso do Sul, Brazil
-
Mariana Scaranti
São Paulo, São Paulo, Brazil
-
Mateus Bongers Alessandretti
Porto Alegre, Rio Grande do Sul, Brazil
-
Micheline Campos Rezende
Muriaé, Minas Gerais, Brazil
-
Monique Celeste Tavares
São Paulo, São Paulo, 01509-900, Brazil
-
Márcia Cristina Colares Régis de Araújo
Fortaleza, Ceará, 60135285, Brazil
-
Rafaela Kirchner Piccoli
Ijuí, Rio Grande do Sul, Brazil
-
Raphael Luzorio Fernandes
Cachoeiro de Itapemirim, Espírito Santo, Brazil
-
Ruffo de Freitas Junior
Goiânia, Goiás, Brazil
-
Sabina Bandeira Aleixo
Cachoeiro de Itapemirim, Espírito Santo, Brazil
-
Sâmio Pimentel Ferreira
Belém, Pará, 66035265, Brazil
-
Sérgio Lunardon Padilha
Curitiba, Paraná, Brazil
-
Tomas Reinert
Caxias do Sul, Rio Grande do Sul, Brazil
-
William Hiromi Fuzita
Manaus, Amazonas, 69057205, Brazil